Manufacturing

Articles

New data highlights ability of the SQZ  cell therapy platform to preserve cellular functions.

SQZ Biotech Discusses Potential Benefit of Cell Therapy Platform

The acquisition will allow Lonza to further develop technology for scalable autologous cell-therapy manufacturing.

Lonza Acquires a Controlling Stake in Octane Biotech for Cell Therapy Technology

The companies will develop and commercialize ARO-HBV, a Phase I/II subcutaneous, ribonucleic acid interference therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.

Janssen, Arrowhead Enter $3.7-Billion Partnership to Treat Hep B

The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.

GSK, Hitachi Chemical in T-Cell Manufacturing Pact

GE Healthcare, Cobra Biologics, and the Centre for Process Innovation (CPI) have entered into a collaboration to advance manufacturing of adeno-associated virus vectors for gene therapy.

GE Healthcare, Cobra Biologics, and CPI Team Up for AAV Vector Manufacturing

FDA awarded nearly $3 million in grants for continuous manufacturing and other advanced manufacturing technologies as part of the agency’s efforts to ensure a robust and reliable supply of biological products.

FDA Awards Five Grants for Advanced Biomanufacturing Research

The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.

Lonza Expands Product Lifecycle Management Capabilities

Bio-Rad introduces CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q resin resin for process protein purification.

Chromatography Resin Designed to Boost Process-Scale Productivity

The combined companies will provide research- and clinical-grade human immune cells, blood products, and related services.

Key Biologics and Astarte Biologics Merge

Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.

Manufacturing, Cell Therapies